In a Frankfurt asylum in 1901, a physician sat beside a frightened 51-year-old woman named Auguste Deter. She could no longer recall her own name, and when the doctor asked her to write it, she said quietly, “I have lost myself.” That doctor was Alois Alzheimer, and the strange changes he later found in her brain — sticky clumps and twisted fibres — would give a name to one of medicine’s most stubborn mysteries. For most of the century that followed, families faced Alzheimer’s disease with almost nothing to offer but comfort. This Alzheimer’s drug research timeline traces the long, patient road from that first case to today — through the discovery of amyloid-beta and tau, decades of heartbreaking trial failures, and the recent arrival of the first medicines shown to modestly slow the disease. It is a story of science advancing not in a single leap, but through thousands of small, hard-won steps.
Alzheimer’s disease is the most common cause of dementia, a progressive loss of memory and thinking caused by damage that builds in the brain over many years. Two hallmark changes — amyloid-beta plaques between nerve cells and tau tangles inside them — were identified across the 1980s, giving drug developers targets to aim at.
For decades almost every drug failed; the older medicines (donepezil, memantine) ease symptoms but do not change the disease. That changed with lecanemab (2023) and donanemab (2024), the first therapies proven to slow decline in early Alzheimer’s by clearing amyloid — a modest benefit that comes with real risks and careful monitoring. Newer blood biomarkers, tau-targeting drugs and AI-assisted discovery are active areas of research, not established cures.
The ideas behind this history — what Alzheimer’s is, why it was so hard to treat, and why the new drugs work the way they do.
To follow this timeline, it helps to know what is actually going wrong inside the brain. Alzheimer’s disease is a form of neurodegeneration — the slow death of nerve cells (neurons) and the connections between them. It is the leading cause of dementia, the umbrella term for a serious loss of memory, reasoning and independence. The damage begins quietly, often 15 to 20 years before the first symptoms, which is one reason it has been so hard to catch and to treat.
Two abnormal proteins define the disease. Amyloid-beta is a sticky fragment that clumps together into plaques in the spaces between neurons. Tau is a protein that normally supports a neuron’s internal scaffolding; in Alzheimer’s it twists into tangles inside the cell. Most researchers believe amyloid builds up first and helps trigger the tau damage and inflammation that ultimately kill neurons — the influential amyloid cascade hypothesis. It is widely supported but still debated, because clearing amyloid has produced only modest benefits so far.
Three reasons stand out. First, the brain is protected by the blood-brain barrier, which blocks most drugs. Second, by the time symptoms appear the disease is already advanced, so many treatments may simply have been given too late. Third, Alzheimer’s is not one simple fault but a tangle of amyloid, tau, inflammation, blood-vessel damage and genetics — hitting a single target rarely fixes the whole picture. The result was one of the highest failure rates in medicine, and years in which no genuinely new drug reached patients.
Two things. Engineers finally built monoclonal antibodies — lab-made immune proteins — that cross into the brain well enough to strip out amyloid plaques, and large trials showed this can modestly slow decline when started early. At the same time, new blood tests and brain scans made it possible to find the disease sooner and confirm who actually has amyloid. Together, better targeting and better timing turned decades of failure into the first real, if limited, progress.
Between the late 1990s and the 2010s, more than 200 Alzheimer’s drug candidates were tested and abandoned, and pharmaceutical companies poured in tens of billions of dollars. Why the graveyard? Many trials enrolled people whose disease was already too far along; some drugs never proved they hit their target in the brain; and early amyloid antibodies either cleared too little plaque or caused dangerous brain swelling. Crucially, each failure taught something — better trial design, earlier diagnosis, biomarker confirmation and safer antibody engineering — that made the eventual successes of lecanemab and donanemab possible.
The big phases of Alzheimer’s science, for quick reference. Full detail follows in the timeline below.
| Era | Years | Defining focus |
|---|---|---|
| Discovery | 1906–1970s | Alzheimer describes the disease; it is slowly recognised as a major illness |
| Finding the targets | 1984–1993 | Amyloid-beta, tau and the APOE4 gene identified; the amyloid hypothesis forms |
| Symptom drugs | 1993–2003 | Cholinesterase inhibitors and memantine ease symptoms but not the disease |
| The failure decade | 2002–2016 | Wave after wave of anti-amyloid and other trials fail |
| First disease-slowing drugs | 2021–2024 | Aducanumab, then lecanemab and donanemab clear amyloid |
| Earlier and broader | 2025–present | Blood tests, at-home dosing, tau drugs, prevention and AI-guided discovery |
Reverse chronological — today first, the first case last. Each entry notes what happened, why it mattered for patients and future research, and how firmly it is established. “Impact” and evidence labels are clearly marked editorial summaries.
For the first time, doctors treating early Alzheimer’s can offer more than symptom relief. Two anti-amyloid antibodies, lecanemab and donanemab, are in use in the United States and other countries, backed by trials showing a modest slowing of decline. Diagnosis is shifting too, as blood biomarker tests spread beyond specialist centres. Yet reality is sober: the drugs suit only a minority of patients caught early, require repeated infusions and MRI safety scans, and deliver benefits measured in months, not miracles. Researchers now race to combine amyloid clearance with tau-targeting drugs and prevention.
Two practical breakthroughs arrived. In May 2025, the FDA cleared the first blood test to help diagnose Alzheimer’s — the Lumipulse pTau217/amyloid ratio — which matched brain PET scans closely in validation and offers a far less invasive alternative to spinal taps. Then in August 2025, regulators approved a subcutaneous, at-home form of lecanemab (Leqembi Iqlik) for maintenance dosing, injectable in seconds. For patients, this points toward earlier, cheaper diagnosis and treatment that fits into daily life. For research, cheap blood markers make prevention trials — treating people before symptoms — finally feasible.
On 2 July 2024, the FDA approved donanemab (Kisunla), Eli Lilly’s anti-amyloid antibody, for early symptomatic Alzheimer’s. In its main trial it slowed decline by about a third in patients with less tau, and its design allows some people to stop treatment once plaques are cleared. Months earlier, in January 2024, Biogen discontinued the controversial first drug, aducanumab (Aduhelm), to focus on lecanemab. For patients, a second effective option meant more choice; for the field, donanemab’s “treat and stop” approach reframed how these expensive drugs might be used.
This was the pivotal year. In July 2023, the FDA granted full (traditional) approval to lecanemab (Leqembi), developed by Eisai and Biogen, after its large CLARITY-AD trial showed it slowed cognitive decline by about 27% over 18 months in early Alzheimer’s. For the first time, a rigorous trial had proven that removing amyloid changes the disease’s course, however modestly. For patients, it opened a genuine treatment path; for research, it validated the amyloid strategy after decades of doubt — while also confirming risks of brain swelling and bleeding that demand careful monitoring.
In June 2021, the FDA gave accelerated approval to aducanumab (Aduhelm) — the first drug ever approved to target Alzheimer’s underlying biology. It was immediately divisive: the agency’s own advisory panel had voted against it because the two trials disagreed on whether it worked, and several advisers resigned. Medicare sharply restricted coverage, and uptake was tiny. For patients, the practical benefit was uncertain; for the field, the episode was a hard lesson in evidence and trust — yet it also proved regulators would approve amyloid-clearing drugs, clearing a path for the stronger data behind lecanemab and donanemab.
Governments finally treated Alzheimer’s as an emergency. The U.S. National Alzheimer’s Project Act (2011) and its 2012 national plan set a goal of effective treatment, and research funding rose steeply; a 2013 G8 dementia summit globalised the push. Yet these same years were littered with high-profile trial failures — anti-amyloid antibodies such as bapineuzumab and solanezumab, and many others, missed their goals. For patients, hope repeatedly rose and fell; for research, the pattern forced a crucial rethink: treat earlier, confirm amyloid with scans, and design smarter trials.
For a century, amyloid plaques could be confirmed only at autopsy. That changed with amyloid PET imaging: a radioactive tracer called Pittsburgh Compound B, reported in 2004, made plaques visible in living patients for the first time. Later tracers gained FDA approval. For patients, it meant more accurate diagnosis; for research, it was transformative — trials could now enroll only people who truly had amyloid, and could measure whether a drug actually removed it. Much of the later success in drug development rests on this ability to see the target.
The FDA approved memantine (Namenda), the first drug for moderate-to-severe Alzheimer’s and the first to work by a new route. Rather than boosting acetylcholine like the earlier drugs, memantine calms glutamate, a signalling chemical that can overexcite and damage neurons. For patients, it offered modest help with daily function in later stages and could be combined with donepezil. For research, it showed Alzheimer’s might be tackled from more than one angle — though, like the cholinesterase inhibitors, it treats symptoms rather than the disease itself.
In 1999, scientists showed that a vaccine against amyloid could clear plaques from the brains of mice — an electrifying result that suggested the immune system could be turned against the disease. A human trial (AN1792) followed, but was halted in 2002 when some participants developed dangerous brain inflammation. For patients, it was a painful setback; for research, it was a landmark: it proved amyloid could be removed from the human brain and pointed the way toward safer monoclonal antibodies — the exact approach that would later succeed.
The FDA approved donepezil (Aricept), which became the world’s most widely used Alzheimer’s medicine. Like the flawed first drug tacrine, it is a cholinesterase inhibitor: it slows the breakdown of acetylcholine, a chemical vital to memory that is depleted in Alzheimer’s. Donepezil was easier to take and gentler on the liver, and rivastigmine and galantamine soon joined it. For patients, these drugs can ease memory and thinking symptoms for a time; for research, they confirmed the cholinergic hypothesis — but also its ceiling, since they never slowed the disease.
Two milestones landed together. The FDA approved tacrine (Cognex), the first drug ever for Alzheimer’s — a breakthrough in principle, though frequent liver side effects limited its use. That same year, researchers at Duke identified APOE4, a common gene variant that is the strongest genetic risk factor for the common, late-onset form of the disease. For patients, APOE4 began to explain why Alzheimer’s runs in some families; for research, it opened the door to precision medicine — and, decades on, APOE4 status now helps predict who is most at risk of side effects from anti-amyloid drugs.
Scientists proposed the idea that would guide a generation of research: the amyloid cascade hypothesis, which holds that a buildup of amyloid-beta is the first domino, triggering tau tangles, inflammation and neuron death. Rare inherited mutations that cause early-onset Alzheimer’s all affect amyloid, giving the theory strong support. For research, it focused enormous effort — and money — on clearing amyloid. It remains the dominant but debated framework: critics note that removing plaques has yielded only modest benefits, and argue tau and other factors deserve more attention.
Researchers located the gene for amyloid precursor protein (APP) — the parent molecule that amyloid-beta is cut from — on chromosome 21. The location was a revelation: people with Down syndrome, who carry an extra copy of chromosome 21, almost all develop Alzheimer’s-type brain changes, neatly linking extra APP to the disease. For research, finding APP and later mutations in it gave a molecular anchor for the whole amyloid story and enabled the first genetically engineered mouse models, the workhorses of drug testing ever since.
Two years after amyloid, scientists identified the main ingredient of the other hallmark lesion. The neurofibrillary tangles inside dying neurons were shown to be made of an abnormal, over-modified form of the protein tau. Normally tau stabilises a neuron’s transport tracks; in Alzheimer’s it detaches and clumps, and the spread of tau tracks closely with where symptoms appear. For research, tau became the second great target — and, because it correlates so well with cognitive decline, a leading focus of today’s experimental drugs aimed at the next generation of treatment.
A foundational moment: George Glenner and Caine Wong isolated and sequenced amyloid-beta, the protein at the heart of Alzheimer’s plaques. For the first time the disease had a defined molecular culprit that scientists could name, study and eventually try to target. For research, everything that followed — the APP gene, the amyloid cascade hypothesis, and every anti-amyloid drug — flows from this identification. It converted Alzheimer’s from a vaguely understood affliction into a biochemical problem that modern medicine knew how to attack.
For decades, “Alzheimer’s” meant only the rare early-onset cases, while the far more common memory loss of old age was dismissed as inevitable senility. In an influential 1976 editorial, neurologist Robert Katzman argued they were the same disease — making Alzheimer’s one of the nation’s leading causes of death, not a footnote of ageing. For patients and families, it brought recognition and, eventually, funding and advocacy. For research, reframing Alzheimer’s as a common, definable disease — alongside the emerging cholinergic hypothesis — set the stage for the first serious drug hunt.
The eminent psychiatrist Emil Kraepelin, Alzheimer’s colleague and mentor, gave the condition its enduring name — “Alzheimer’s disease” — in the 1910 edition of his widely read psychiatry textbook. For medicine, naming mattered: it lifted the condition from a single case report into a recognised clinical entity that doctors could diagnose and discuss. For research, it fixed a label under which more than a century of study would accumulate, even though the disease itself would remain deeply mysterious for another seventy years.
Where it all began. After his patient Auguste Deter died, Alois Alzheimer examined her brain and, in a 1906 lecture, described the two features that still define the disease: dense plaques between the neurons and twisted tangles within them. He had connected a living person’s tragic loss of memory and self to specific, visible changes in the brain. For medicine, it was the birth of a diagnosis; for research, those two lesions became the north star — the very targets that, more than a hundred years later, the newest drugs are designed to remove.
The approved medicines side by side — what they target, what they offer, and their limits. Benefits are modest and individual; this is educational, not prescribing advice.
| Drug | Year | Target / mechanism | Benefit | Limitations |
|---|---|---|---|---|
| Tacrine (Cognex) | 1993 | Cholinesterase inhibitor | First-ever drug; eased symptoms | Frequent liver toxicity; largely withdrawn |
| Donepezil (Aricept) | 1996 | Cholinesterase inhibitor | Eases memory symptoms for a time | Does not slow disease; nausea, other effects |
| Memantine (Namenda) | 2003 | NMDA (glutamate) blocker | Helps moderate-severe stages | Symptom relief only; modest effect |
| Aducanumab (Aduhelm) | 2021 | Anti-amyloid antibody | Cleared amyloid plaques | Unproven benefit; discontinued in 2024 |
| Lecanemab (Leqembi) | 2023 | Anti-amyloid (protofibrils) | Slowed decline ~27% in early disease | Infusions; brain swelling/bleeding risk; MRI |
| Donanemab (Kisunla) | 2024 | Anti-amyloid antibody | Slowed decline ~29–35% in early disease | Same risks; only early-stage patients |
Read as a whole, this history is not a straight climb but a chain of instructive failures. Tacrine’s toxicity taught safer chemistry. The halted 1999–2002 vaccine proved amyloid could be cleared and pointed to antibodies. A decade of missed trials taught the field to treat earlier and confirm the target. Even the aducanumab controversy set the regulatory and scientific stage for stronger evidence. Each failed trial genuinely improved the next generation of therapies — which is why the modest wins of 2023–2024 rest on the shoulders of everything that did not work.
How the visible signs of Alzheimer’s map onto the biology — and which approaches aim at each.
| What patients experience | Underlying brain change | What treatment targets it |
|---|---|---|
| Early memory loss, repeating questions | Loss of acetylcholine signalling | Cholinesterase inhibitors (donepezil) |
| Worsening confusion, agitation (later) | Glutamate overactivity, neuron loss | Memantine |
| Underlying, years before symptoms | Amyloid-beta plaque buildup | Anti-amyloid antibodies (lecanemab, donanemab) |
| Spreading, tracks with decline | Tau tangles inside neurons | Tau drugs (experimental, under study) |
| Higher personal risk | APOE4 gene, inflammation, vessels | Precision medicine and prevention research |
Selected figures that show the scale of the challenge. Values are approximate and drawn from bodies such as the WHO, the Alzheimer’s Association and peer-reviewed research.
| Measure | Approximate figure | Note |
|---|---|---|
| People living with dementia worldwide | Over 55 million | Alzheimer’s is the most common cause (WHO) |
| Projected cases by 2050 | Around 139 million | Driven by ageing populations |
| Share of dementia that is Alzheimer’s | Roughly 60–70% | Often mixed with other types |
| Drug-trial failure rate (historic) | Well over 99% | Among the highest in medicine |
| Lecanemab slowing of decline | About 27% | Over 18 months, early disease (CLARITY-AD) |
| Silent phase before symptoms | 15–20 years | Damage builds long before diagnosis |
| Blood test accuracy vs PET | Around 90%+ concordance | First FDA-cleared test, 2025 |
The most-watched frontiers are all still under investigation. Tau-targeting drugs aim at the protein that tracks best with symptoms. Next-generation antibodies such as brain-shuttle designs try to clear plaque faster with less swelling. Blood biomarkers promise earlier, cheaper detection and true prevention trials. Gene therapies, anti-inflammatory approaches and AI-assisted drug discovery are expanding the pipeline. And researchers increasingly test combination therapy — hitting amyloid and tau together. These are promising directions, not proven treatments; families should treat headlines about any “breakthrough” with measured hope.
The people, molecules, drugs and organisations at the centre of the Alzheimer’s story.
The most common cause of dementia; a progressive neurodegenerative disease marked by amyloid plaques, tau tangles and the loss of neurons.
German physician who, in 1906, first linked a patient’s dementia to plaques and tangles in the brain, defining the disease that bears his name.
Alzheimer’s first documented patient, whose case at age 51 became the founding record of the disease.
A protein fragment that clumps into plaques between neurons; isolated in 1984 and the main target of today’s antibody drugs.
A protein that twists into tangles inside neurons; identified in 1986 and a leading target for the next generation of experimental drugs.
The strongest common genetic risk factor for late-onset Alzheimer’s, identified in 1993; it also affects the safety of anti-amyloid drugs.
The first drug proven to slow early Alzheimer’s, fully FDA-approved in 2023; an anti-amyloid antibody from Eisai and Biogen.
Eli Lilly’s anti-amyloid antibody, FDA-approved in 2024, notable for a treat-and-stop dosing approach.
The mainstay symptom drugs since the 1990s and 2000s; they ease memory or later-stage symptoms but do not slow the disease.
The dominant, still-debated theory that amyloid buildup triggers the tau damage and inflammation that drive Alzheimer’s.
Tests such as pTau217 that detect Alzheimer’s biology from a blood draw; the first was FDA-cleared in 2025.
The U.S. regulator whose approvals — and controversies — have shaped which Alzheimer’s treatments reach patients.
The National Institutes of Health and National Institute on Aging fund much of the world’s Alzheimer’s research.
A leading non-profit funding research, guiding clinicians and supporting families affected by the disease.
Surprising details that reveal how winding the road to treatment really was.
Continue through connected histories of medicine, the brain and technology on AiTimeline.
24 clear, evidence-based answers on Alzheimer’s drugs, diagnosis and research. Educational only — not a substitute for medical advice.
A closing word, with honesty and with hope.
If you are reading this because someone you love is slipping away, hold two truths at once. The first is hard: today’s treatments are not cures. The drugs now available can, at best, slow early Alzheimer’s modestly, they help only some people, and they carry real risks that must be weighed carefully with a doctor. Anyone who promises a miracle is not telling you the truth.
The second truth is genuinely hopeful. In little more than a century, Alzheimer’s has gone from an untreatable mystery — a brain examined only after death — to a disease we can name, see in a living person, detect from a drop of blood, and, for the first time, meaningfully slow in its early stages. Every failed trial along the way quietly taught the next one how to do better. That is how real medical progress usually happens: not in a single triumphant leap, but step by patient step.
For families now, the most powerful tools are often the simplest: seek help early, when treatments work best; ask a specialist what is right for your situation; look after heart health, sleep, activity and connection; and lean on organisations like the Alzheimer’s Association for support. Auguste Deter once said she had “lost herself.” More than a hundred years later, the people working to answer her illness have not lost hope — and, slowly, they are changing what her diagnosis means.
This timeline is for education and is not medical advice. Alzheimer’s science is advancing quickly; approvals, trial results and guidelines can change. Details here are drawn from authoritative sources including the U.S. FDA, the National Institute on Aging (NIH), the Alzheimer’s Association and peer-reviewed journals, and are clearly labelled as established, emerging or experimental. For any decision about diagnosis, medication or care, consult a qualified healthcare professional who knows the individual’s situation. Last reviewed against current sources on 16 July 2026.